Chronic Pain News and Research

RSS

FDA approves Covidien's morphine sulfate oral solution for chronic pain in opioid-tolerant patients

Covidien, a leading global provider of healthcare products, today announced that the U.S. Food and Drug Administration (FDA) recently granted approval to the company's Mallinckrodt business for morphine sulfate oral solution, used to relieve moderate to severe acute and chronic pain in opioid-tolerant patients. The solution will be available as a generic in 100 milligrams per 5 mL (20 milligrams per 1 mL).

1 Aug 2011

Pain intensity and location can predict chronic low back pain

By some estimates, up to 85 percent of Americans have experienced low back pain and research reported in The Journal of Pain showed that pain intensity ratings, pain location and sensory and affective variables differ among individuals with acute and chronic low back pain. In some cases, these factors might be predictive of which acute pain patients may develop chronic pain.

29 Jul 2011

Arterial spin labeling shows areas of brain activity in chronic low back pain patients

Research from Brigham and Women's Hospital (BWH) uses a new imaging technique, arterial spin labeling, to show the areas of the brain that are activated when patients with low back pain have a worsening of their usual, chronic pain.

28 Jul 2011

Yoga reduces symptoms of chronic pain in women with fibromyalgia

A new study by York University researchers finds that practicing yoga reduces the physical and psychological symptoms of chronic pain in women with fibromyalgia.

28 Jul 2011

Researchers draw on ontology to define pain

All over the world, patients with chronic pain struggle to express how they feel to the doctors and health-care providers who are trying to understand and treat them. Now, a University at Buffalo psychiatrist is attempting to help patients suffering from chronic pain and their doctors by drawing on ontology, the branch of philosophy concerned with the nature of being or existence.

28 Jul 2011

QRxPharma raises A$25 million, announces A$10.4 million Rights Issue

QRxPharma Limited is pleased to announce the successful completion of a placement to institutions and professional investors raising A$25 million which was significantly oversubscribed. The Placement was very well supported by both existing and new investors including Australia, US and UK based fund managers.

25 Jul 2011

BDSI completes BEMA Buprenorphine Phase 3 trial on chronic pain

BioDelivery Sciences International, Inc. announced today that the last patient has completed the randomized portion of its Phase 3 clinical trial assessing the efficacy and safety of BEMA Buprenorphine for the treatment of moderate to severe chronic pain, signifying completion of the trial.

25 Jul 2011

Homeless people report using street drugs to treat their pain

Chronic pain is not managed well in the general population and it's an even greater challenge for homeless people, according to new research by St. Michael's Hospital.

22 Jul 2011

Study finds high prevalence of prescription pain medication addiction in chronic patients

A new study by Geisinger Health System researchers finds a high prevalence of prescription pain medication addiction among chronic pain patients.

22 Jul 2011

Dealing with chronic pain

For people with severe chronic pain like Kelly Young and Teresa Shaffer—both of whom have become patient advocates —coping with agony is a fact of life. Young suffers from rheumatoid arthritis while Shaffer's pain is linked primarily to another degenerative bone disease.

21 Jul 2011

Young people with serious genetic blood disorder are not getting right help at school

A new study suggests young people with a serious genetic blood disorder are not getting the right help at school, especially pupils who miss lessons due to sickness.

20 Jul 2011

Convergence initiates CNV1014802 Phase II study in lumbosacral radiculopathy

Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines, today announces that the Phase II proof of concept study with CNV1014802 for treating pain associated with lumbosacral radiculopathy (LSR) has started.

19 Jul 2011

Chronic self-reported NSAID use associated with increased risk of adverse events in hypertensive patients with CAD

A study published in the July issue of The American Journal of Medicine, reports that among hypertensive patients with coronary artery disease, chronic self-reported use of non-steroidal anti-inflammatory drugs (NSAIDs) was associated with an increased risk of adverse events during long-term follow-up. Long-term NSAID use is common for treatment of chronic pain.

13 Jul 2011

FDA clears St. Jude Medical's Epiducer lead delivery system for neurostimulation

St. Jude Medical, Inc., a global medical device company, today announced the U.S. Food and Drug Administration (FDA) clearance and limited market release of the Epiducer lead delivery system for neurostimulation therapy.

13 Jul 2011

New genetic clues about ankylosing spondylitis

A study involving over 5,000 people living with the joint disorder ankylosing spondylitis has identified a series of genetic variants associated with increased susceptibility to the condition as well as providing new clues to how the condition may be treated in the future.

11 Jul 2011

Researchers find new molecule that controls pain sensitivity from UVB irradiation

Researchers at King's College London have found a molecule in the body which controls sensitivity to pain from UVB irradiation, identifying it as a new target for medicines to treat pain caused by other common inflammatory conditions such as arthritis.

7 Jul 2011

IOM report highlights need for changes in pain management

Defining pain as "a major public health problem," the Institute of Medicine offered recommendations to make systemic and cultural changes in how pain could either be prevented or managed better.

1 Jul 2011

IOM report can set the stage for improvements in pain care, says APS

The American Pain Society (APS) said that "Relieving Pain in America: A Blueprint for Transforming Prevention, Treatment, and Research, the report submitted to Congress today by the Institute of Medicine, is a major step forward in addressing the nation's leading public health problem - untreated and undertreated chronic pain.

30 Jun 2011

100 million Americans suffer pain - many in silence

According to a report released by the Institute of Medicine Wednesday, nearly a third of Americans experience long-lasting pain and too often feel stigma rather than relief from a health care system poorly prepared to treat them. Chronic pain is costing the nation at least $558 billion a year in medical bills, sick days and lost productivity, the report found. That's more than the cost of heart disease, the top killer.

30 Jun 2011

Cipher grants Vertical exclusive U.S. distribution rights to CIP-TRAMADOL ER

Cipher Pharmaceuticals Inc. today announced that it has entered into a definitive distribution and supply agreement with Vertical Pharmaceuticals, Inc., a U.S.-based specialty pharmaceutical company, under which Cipher has granted Vertical the exclusive right to market, sell and distribute CIP-TRAMADOL ER in the United States.

29 Jun 2011